Title:
PNH (Paroxysmal Nocturnal Hemoglobiniuria) Registry View
Indication:
Miscellaneous
Location:
Texas Oncology-Amarillo Cancer Center
Phase: N/A
Title:
Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View
Indication:
Hematologic
Location:
Texas Oncology-Amarillo Cancer Center
Title:
STAR INCB054828 Urothelial FGF/FGFR View
Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)
Indication:
Bladder Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Bladder Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: III
Title:
STAR Ph3 BLU-285 vs Regorafenib GIST View
Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Indication:
GI Stromal Tumor (GIST)
Location:
Texas Oncology-Amarillo Cancer Center
Phase: III
Title:
STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View
Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)
Indication:
Lung Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: III
Title:
STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View
Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)
Indication:
Lung Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: III
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Indication:
Lymphomas
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR Ph2 Itacitinib +/- Ruxo in MF View
Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Indication:
Myelofibrosis
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
PREAMBLE - Observational in 1L & R/R MM View
Description: CA204-008: Prospective Research Assessment in Multiple Myeloma: an Observational Evaluation (PREAMBLE)
Indication:
Myelomas
Location:
Texas Oncology-Amarillo Cancer Center
Title:
STAR Ph2 Rucaparib mCRPC (TRITON 2) View
Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052
Indication:
Prostate Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: III
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR Ph2 INCMGA00012 mSCAC View
Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)
Indication:
Rectal Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR INCB054828 Urothelial FGF/FGFR View
Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Urothelial Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II